Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11002
Plant phosphates, phytate and pathological calcifications in chronic kidney disease
Identifiers
ISSN: 0211-6995
eISSN: 1989-2284
WOS ID: 000395497000004
PMID: 27697413
Embase PUI: L614437246
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2017-01Document type
review articleCitation
Buades JM, Sanchis P, Perello Bestard J, Grases F. Plant phosphates, phytate and pathological calcifications in chronic kidney disease. Nefrologia. 2017 Jan;37(1):20-8. Epub 2016 Sep 30.Abstract
Phytate, or myo-inositol 1,2,3,4,5,6-hexakis dihydrogen phosphate (InsP6), is a naturally occurring phosphorus compound that is present in many foods, mainly legumes, whole grains and nuts. Patients with chronic kidney disease (CKD) have cardiovascular disease mortality up to 30 times higher than the general population. Vascular calcifications (VCs) directly contribute to overall morbidity and mortality, especially in CKD. In part, this high mortality is due to elevated levels of phosphorus in the blood. Therefore, control of dietary phosphorus is essential. Dietary phosphorus can be classified according to its structure in organic phosphorus (plant and animal) and inorganic (preservatives and additives). Plant phosphorus (legumes and nuts), mainly associated with InsP6, is less absorbable by the human gastrointestinal tract as the bioavailability of phosphorous from plant -derived foods is very low. Recent data indicate that restriction of foods containing plant phosphates may compromise the adequate supply of nutrients that have a beneficial effect in preventing cardiovascular events, such as InsP6 or fibre found in legumes and nuts. Experimental studies in animals and observational studies in humans suggest that InsP6 can prevent lithiasis and VCs and protect from osteoporosis. In conclusion, we need prospective studies to elucidate the potential benefits and risks of phytate (InsP6) through the diet and as an intravenous drug in patients on haemodialysis.
Publisher version
https://dx.doi.org/10.1016/j.nefro.2016.07.001Keywords
Chronic kidney diseaseHyperphosphataemia
Phytate
Phytic acid
Vascular calcifications
Calciphylaxis
MeSH
AntioxidantsCardiovascular Diseases
Chronic Kidney Disease-Mineral and Bone Disorder
Urolithiasis
Molecular Structure
Biological Availability
Humans
Calcinosis
Fabaceae
Observational Studies as Topic
Cross-Sectional Studies
Nuts
Male
Phosphates
Prospective Studies
Arteriosclerosis
Phytic Acid
Rats
Animals
Phosphorus, Dietary
Hyperphosphatemia
Renal Insufficiency, Chronic
Osteoporosis
DeCS
AnimalesTrastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica
Fósforo Dietético
Estudios Observacionales como Asunto
Arteriosclerosis
Masculino
Disponibilidad Biológica
Estudios Transversales
Ácido Fítico
Calcinosis
Hiperfosfatemia
Ratas
Humanos
Nueces
Fosfatos
Estudios Prospectivos
Fabaceae
Urolitiasis
Osteoporosis
Insuficiencia Renal Crónica
Enfermedades Cardiovasculares
Antioxidantes
Estructura Molecular
This item appears in following Docusalut collections
Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científicaHospital Universitario Son Llàtzer - HUSLL > Comunicación científica